देश: कनाडा
भाषा: अंग्रेज़ी
स्रोत: Health Canada
CEFEPIME (CEFEPIME HYDROCHLORIDE)
APOTEX INC
J01DE01
CEFEPIME
1G
POWDER FOR SOLUTION
CEFEPIME (CEFEPIME HYDROCHLORIDE) 1G
INTRAMUSCULAR
15G/50G
Prescription
FOURTH GENERATION CEPHALOSPORINS
Active ingredient group (AIG) number: 0150504004; AHFS:
APPROVED
2017-08-17
Page 1 of 40 PRODUCT MONOGRAPH Pr APO-CEFEPIME Cefepime for Injection USP 1 g and 2 g cefepime per vial (as cefepime hydrochloride) Antibiotic _ _ APOTEX INC. DATE OF PREPARATION: 150 Signet Drive, NOVEMBER 12, 2019 Toronto, Ontario M9L 1T9 Control Number: 231676 _ _ Page 3 of 40 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ............................................................ 3 SUMMARY PRODUCT INFORMATION ............................................................................... 3 INDICATIONS AND CLINICAL USE .................................................................................... 3 CONTRAINDICATIONS .......................................................................................................... 5 WARNINGS AND PRECAUTIONS ........................................................................................ 5 ADVERSE REACTIONS .......................................................................................................... 8 DRUG INTERACTIONS......................................................................................................... 10 DOSAGE AND ADMINISTRATION .................................................................................... 11 OVERDOSAGE ....................................................................................................................... 16 ACTION AND CLINICAL PHARMACOLOGY ................................................................... 16 STORAGE AND STABILITY ................................................................................................ 20 SPECIAL HANDLING INSTRUCTIONS .............................................................................. 20 DOSAGE FORMS, COMPOSITION AND PACKAGING .................................................... 20 PART II: SCIENTIFIC INFORMATION .................................................................................. 21 PHARMACEUTICAL INFORMATION ................................................................................ 21 CLINICAL TRIA पूरा दस्तावेज़ पढ़ें